Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts
Authors:
Open Access
- 11 December 2021
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (4S) , 4791
Abstract
At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.Keywords
This publication has 22 references indexed in Scilit:
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialEuropean Heart Journal, 2021
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart FailureCirculation, 2020
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trialsThe Lancet, 2020
- Sodium–Glucose Co-Transporter 2 Inhibitors and Acute Heart FailureEuropean Journal of Heart Failure, 2020
- Evaluation of the Effect of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR-Reduced TrialEuropean Journal of Heart Failure, 2019
- The Future Treatment of Heart Failure?European Heart Journal, 2018
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- CHRONIC HEART FAILURE IN RUSSIAN FEDERATION: WHAT DO WE KNOW AND WHAT TO DORussian Journal of Cardiology, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015